Octapharma AG - Strategic SWOT Analysis Review

November 2021 | 35 pages | ID: OE151A78EEDEN
GlobalData

Abstracts

Octapharma AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Octapharma AG (Octapharma) is a human protein product manufacturer that focuses on developing and producing medicines through human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy, haematology and critical care therapeutic areas. It sources majority of plasma from company-owned donation centers. Octapharma owns plasma donation centers in the US and Germany, and owns state-of-the-art production facilities in Austria, Germany, France, Mexico and Sweden. The company’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labelling, packaging, storage and distribution. Octapharma is headquartered in Lachen, Switzerland.

Octapharma AG Key Recent Developments

May 28,2021: MOTIVATE enrolls first patient in the US
Jan 21,2021: Akron Biotech, Octapharma enter Human AB Serum global production deal
Jan 11,2021: Octapharma to demonstrate ongoing commitment to improving the long-term health of people with Haemophilia A at the 14th EAHAD Annual Congress
Jan 07,2021: Octapharma selects Model N Revenue Cloud for Life Sciences
Jul 13,2020: New data to be presented at the ISTH 2020 virtual congress demonstrating Octapharma’s commitment to patients With bleeding disorders

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Octapharma AG - Key Facts
Octapharma AG - Key Employees
Octapharma AG - Key Employee Biographies
Octapharma AG - Major Products and Services
Octapharma AG - History
Octapharma AG - Company Statement
Octapharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Octapharma AG - Business Description
R&D Overview
Octapharma AG - Corporate Strategy
Octapharma AG - SWOT Analysis
SWOT Analysis - Overview
Octapharma AG - Strengths
Octapharma AG - Weaknesses
Octapharma AG - Opportunities
Octapharma AG - Threats
Octapharma AG - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Octapharma AG, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

May 28, 2021: MOTIVATE enrolls first patient in the US
Jan 21, 2021: Akron Biotech, Octapharma enter Human AB Serum global production deal
Jan 11, 2021: Octapharma to demonstrate ongoing commitment to improving the long-term health of people with Haemophilia A at the 14th EAHAD Annual Congress
Jan 07, 2021: Octapharma selects Model N Revenue Cloud for Life Sciences
Jul 13, 2020: New data to be presented at the ISTH 2020 virtual congress demonstrating Octapharma’s commitment to patients With bleeding disorders
Apr 07, 2020: Takeda teams up with plasma firms for Covid-19 hyperimmune therapy
Feb 14, 2020: Octapharma group delivered strong growth in both sales and operating income in 2019

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Octapharma AG, Key Facts
Octapharma AG, Key Employees
Octapharma AG, Key Employee Biographies
Octapharma AG, Major Products and Services
Octapharma AG, History
Octapharma AG, Other Locations
Octapharma AG, Subsidiaries
Octapharma AG, Key Competitors
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Octapharma AG, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021